Mavatrep (JNJ‐39439335) is a TRPV1 receptor selective competitive antagonist.[1] It is an investigational analgesic that may be a potential treatment for pain and/or inflammation.
Clinical data | |
---|---|
Other names | JNJ-39439335 |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
DrugBank |
|
ChemSpider |
|
UNII |
|
ChEMBL |
|
CompTox Dashboard (EPA) |
|
Chemical and physical data | |
Formula | C25H21F3N2O |
Molar mass | 422.451 g·mol−1 |
3D model (JSmol) |
|
| |
|
Phase I trials have been completed in healthy Japanese and Caucasian volunteers.[1][2]
Potential common adverse effects include thermohypoesthesia, chills, feeling cold, and feeling hot.[2]
When administered orally once a day, mavatrep reached steady-state in healthy volunteers in approximately 14 days.[2] It has a relatively long half life between 68 and 101 hours in Japanese subjects and between 82 and 130 hours in Caucasian subjects.[2]
Mavatrep is largely eliminated nonrenally. Mavatrep appears to be metabolized into two primary metabolites which are also eliminated nonrenally.[2]